Testing effectiveness (Phase 2)Looking for participantsNCT06394674
What this trial is testing
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Who this might be right for
Non-Small Cell Lung Cancer
Changhai Hospital 84